Seer, Inc.

NASDAQ:SEER

Biotechnology

Healthcare
$1.44 +0.29%

+$0.01 today

Market cap
$80.37M
Beta
1.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.26
52W Low $1.65High $2.41

Volume 0.23M

Average 0.32M

SEER Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Seer, Inc.NASDAQ: SEER

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $8.81M fell 22.4% year over year, behind the -11.2% change in trailing-twelve-month research & development. Sequentially, it fell 9.6% from the prior quarter. Over 3 fiscal years it compounded at -6.2% a year.

Context

  • Research & development amounted to 234.3% of revenue in FY2025, down 128.4 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -22.4% toward the trailing-twelve-month pace of -11.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.81M-9.6% QoQ
Last fiscal yearDec 2025
$37.77M-25.3% YoY
LTMMar 2026
$41.33M-11.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.4%——
1 year-25.3%——
3-year CAGR-6.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
37.77M USD
Year-over-year change
-25.3%
4-year CAGR
+6.7%

Research & Development vs competitors

How SEER compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -11.2% is the 14th highest of 19, against a peer median of -3.1%.
  • Research & development amounts to 274.8% of revenue for SEER, versus a peer median of 357.8%.
SEER Competitors
Research & Development for SEER and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MNOVMediciNova, Inc.LTM Mar 2026$1.27B USD+18127.2%-7.8%212494.0%
KYMRKymera Therapeutics, Inc.LTM Jun 2026$375.6M USD+29.1%+24.5%357.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M USD+10.2%+18.6%47.3%
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$301.59M USD+72.6%+71.3%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026$188.07M USD+22.3%+26.8%—
GLUEMonte Rosa Therapeutics, Inc.LTM Mar 2026$153.38M USD+23.0%+18.5%357.1%
LYELLyell Immunopharma, Inc.LTM Mar 2026$151.83M USD-11.7%-0.1%489780.6%
SANASana Biotechnology, Inc.LTM Mar 2026$146.28M USD-4.6%-13.1%—
PHVSPharvaris N.V.LTM Sep 2026€132.22M EUR+7.0%+29.5%—
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$116.62M USD-0.1%+21.2%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M USD-11.6%-4.0%291.9%
NKTXNkarta, Inc.LTM Mar 2026$88.91M USD-7.1%-0.2%—
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M USD-9.4%-6.8%290.9%
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
QSIQuantum-Si incorporatedLTM Mar 2026$54.53M USD-11.0%-9.3%2944.3%
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
SEERSeer, Inc.LTM Mar 2026$41.33M USD-11.2%-6.2%274.8%
STTKShattuck Labs, Inc.LTM Mar 2026$36.3M USD-40.4%-24.8%3629.9%
ANTXAN2 Therapeutics, Inc.LTM Mar 2026$23.82M USD-28.9%-5.7%—
Peer median (excluding SEER) —-3.1%-0.1%357.8%

Competitors are the stored peer set for SEER. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.39M14.69M15.18M13.95M16.12M
Cost of Revenue6.77M14.3M13.73M7.12M14.22M
Gross Profit(374K)384K1.45M6.83M1.9M
Gross Margin-5.8%2.6%9.5%49.0%11.8%
Research & Development29.12M45.8M47.44M50.59M37.77M
Selling, General & Admin42.2M52.63M58.95M56.57M42.58M
Operating Expenses71.32M98.43M106.39M106.93M80.35M
Depreciation & Amortization3.56M5.9M5.58M6.18M6.1M
EBITDA(67.61M)(87.07M)(80.7M)(80.33M)(67.3M)
EBITDA Margin-1057.3%-592.9%-531.5%-575.9%-417.5%
Operating Income(71.7M)(98.04M)(104.94M)(100.1M)(78.45M)
Operating Margin-1121.3%-667.6%-691.2%-717.7%-486.7%
Interest Income326K4.6M17.76M16.67M11.52M
Interest Expense22K0000
Other Income / Expenses527K5.08M18.67M13.6M5.05M
Income Before Tax(71.17M)(92.97M)(86.28M)(86.5M)(73.4M)
Pre-Tax Margin-1113.1%-633.1%-568.3%-620.2%-455.4%
Income Tax Expense00098K201K
Net Income(71.17M)(92.97M)(86.28M)(86.6M)(73.6M)
Net Margin-1113.1%-633.1%-568.3%-620.9%-456.6%
EPS (Basic)(1.13)(1.42)(1.35)(1.39)(1.28)
EPS (Diluted)(1.13)(1.42)(1.35)(1.39)(1.28)
Weighted Avg Shares60.86M62.43M63.85M62.35M57.45M
Weighted Avg Shares (Diluted)60.86M62.43M63.85M62.35M57.45M

Seer, Inc.

NASDAQ:SEER

Intrinsic Alpha fair value

Locked

Current Price

$1.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.